Une nouvelle approche pur l'induction de cellules T cytotoxiques specifiques in vivo (original) (raw)
A novel approach to the induction of specific cytolytic T cells in vivo
Victoria ley
Research in immunology
View PDFchevron_right
The cellular immunotherapy of cancer: Current and potential uses of interleukin-2
Jacquelyn Hank
Critical Reviews in Oncology/Hematology, 1989
View PDFchevron_right
Interleukin-2-transduced lymphocytes grow in an autocrine fashion and remain responsive to antigen
Jonathan Treisman
Blood
View PDFchevron_right
Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination
Achim Schneeberger
Proceedings of the National Academy of Sciences, 1995
View PDFchevron_right
Antigenic specificity of the cytolytic T lymphocyte (CTL) response to murine sarcoma virus-induced tumors. I. Preferential reactivity ofin vitro generated secondary CTL with syngeneic tumor cells
C. victor Jongeneel
European Journal of Immunology, 1976
View PDFchevron_right
Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2
Olav de Leeuw
Int J Oncol, 1992
View PDFchevron_right
Lymphokine-activated tumor inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth
Mirella Giovarelli
Journal of Immunology, 1985
View PDFchevron_right
Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors
Cornelis Melief
Journal of Experimental Medicine, 1998
View PDFchevron_right
Generation of tumor-specific cytotoxic T lymphocytesin vivo by combined treatment with inactivated tumor cells and recombinant interleukin-2
Pramod Srivastava
Cancer Immunology Immunotherapy, 1994
View PDFchevron_right
Functional endogenous cytotoxic T lymphocytes are generated to multiple antigens co-expressed by progressing tumors; after intra-tumoral IL-2 therapy these effector cells eradicate established tumors
Delia Nelson
Cancer Immunology, Immunotherapy, 2006
View PDFchevron_right
Murine spontaneous T-cell leukemia constitutively expressing IL-2 receptor—a model for human T-cell malignancies expressing IL-2 receptor
David Naor, Silvia Hajos
International Journal of Cancer, 1990
View PDFchevron_right
Cytotoxic T cells and Cancer Therapy
Sandip Chakraborty
Journal of Experimental Biology and Agricultural Sciences, 2017
View PDFchevron_right
Induction of Antigen-Specific Class I-Restricted Cytotoxic T Cells by Soluble Proteins in vivo
John Morrow
Proceedings of The National Academy of Sciences, 1992
View PDFchevron_right
Induction of H-2-restricted cytotoxic T cells: in vivo induction has the appearance of being unrestricted
Polly Matzinger
Cellular Immunology, 1977
View PDFchevron_right
Tumor-Specific CD4 1 T Lymphocytes from Cancer Patients Are Required for Optimal Induction of Cytotoxic T Cells Against the Autologous Tumor
Michael Papamichail
View PDFchevron_right
Characterization of factors regulating successful immunotherapy using a tumor-specific cytotoxic T lymphocyte clone: Role of interleukin-2, cycling pattern of lytic activity and adhesion molecules
Prakash Nagarkatti
International Journal of Cancer, 1995
View PDFchevron_right
Presentation of peptides by cultured monocytes or activated T cells allows specific priming of human cytotoxic T lymphocytes in vitro
Vincenzo Barnaba
International Immunology, 1995
View PDFchevron_right
In vitro induction of immunological tolerance
Maria Giuseppina Mazzocchi
Cellular Immunology, 1989
View PDFchevron_right
In vitro induction of tumor specific immunity: requirements for T lymphocytes and tumor growth inhibitionin vivo
Hermann Wagner
European Journal of Immunology, 1973
View PDFchevron_right
Synergy between interleukin-2 and prothymosin ? for the increased generation of cytotoxic T lymphocytes against autologous human carcinomas
george stathopoulos
Cancer Immunology, Immunotherapy, 2000
View PDFchevron_right
Adoptive immunotherapy of a syngeneic murine leukemia with a tumor-specific cytotoxic T cell clone and recombinant human interleukin 2: correlation with clonal IL 2 receptor expression
Louis Matis
The Journal of Immunology
View PDFchevron_right
Adjuvant activity of recombinant interleukin 12 in the induction of T cell response against a mouse tumor antigen peptide
S SiLa
Pharmacological Research, 1995
View PDFchevron_right
Immunogenicity and immunosensitivity of ex vivo human carcinomas: interferon ? and tumour necrosis factor ? treatment of tumour cells potentiates their interaction with autologous blood lymphocytes
Luis Carlos Rodriguez Alvarez
Cancer Immunology Immunotherapy, 1995
View PDFchevron_right
Immune reactivity in SL2 lymphoma-bearing mice compared with SL2-immunized mice
Roel Rios Rios
Cancer Immunology Immunotherapy, 1987
View PDFchevron_right
Vaccination with Tumor Cells Engineered to Secrete Interleukin 2-Immunoglobulin G Fusion Protein Induces Tumor Rejection
Horst Von Bernuth
Cancer Research, 1998
View PDFchevron_right
Multiple effects of transfection with interleukin 2 and/or interferon gamma on the behavior of mouse T lymphoma cells
J. Van Ginderachter
Clinical & experimental metastasis, 1998
View PDFchevron_right
Functional role of IL-2 receptors on tumour-infiltrating lymphocytes
R. Zambello
British Journal of Cancer, 1994
View PDFchevron_right
T cell activation: independent induction of killing activity and interleukin 2 secretion in cytolytic hybridomas*
Gideon Berke
European Journal of Immunology, 1989
View PDFchevron_right
Further characterization of cytotoxic T cells generated by short-term culture of human peripheral blood lymphocytes with interleukin-2 and anti-CD3 mAb
Michel Moutschen
Cancer Immunology Immunotherapy, 1996
View PDFchevron_right
Recruitment of alloreactive cytotoxic T lymphocytes by an antigenic peptide
Uwe Staerz
European Journal of Immunology, 1989
View PDFchevron_right
Multiple effects of transfection with interleukin 2 and/or interferon γ on the behavior of mouse T lymphoma cells
J. Van Ginderachter
1998
View PDFchevron_right